Previous 10 | Next 10 |
2023-05-04 17:21:11 ET Alector press release ( NASDAQ: ALEC ): Q1 GAAP EPS of -$0.55. Revenue of $16.5M. For further details see: Alector GAAP EPS of -$0.55, revenue of $16.5M
On track to engage with regulatory authorities on the pivotal Phase 3 INFRONT-3 clinical trial of latozinemab in mid-2023; targeting data readout in early 2025 Plan to present additional results from the entire FTD-C9orf72 cohort in the INFRONT-2 Phase 2 clinical trial of latozinemab du...
SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a corporate presentation at the BofA Securities 2023 Healthcare Conference ...
Alector press release ( NASDAQ: ALEC ): Q4 GAAP EPS of -$0.63 misses by $0.09 . Revenue of $14.44M (+3.1% Y/Y) misses by $11.44M . For further details see: Alector GAAP EPS of -$0.63 misses by $0.09, revenue of $14.44M misses by $11.44M
On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer’s disease in Q3 2023, with data readout expected by Q4 2024 Preparing to engage with regulatory authorities in mid-2023 and targeting data readout from the pivotal INF...
Summary Alector, Inc. has a lot of cash for a small biotech, but it is also trading at cash. Alector, Inc. has a late-stage program in a CNS indication and major big pharma deals. The situation, to say the least, is confusing. Alector, Inc. (ALEC) is a pioneering CNS disea...
AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease Study results in healthy volunteers demonstrated that AL101 increased the level of PGRN, a key regulator of immune activit...
Alector, Inc. ( NASDAQ: ALEC ), a biotech focused on neurodegeneration diseases, shed ~18% Wednesday to reach a new 52-week low as Wall Street turned attention to the company's pipeline after its Q3 2022 results. Alector ( ALEC ) intends to report new data from t...
Alector press release ( NASDAQ: ALEC ): Q3 GAAP EPS of -$0.56 misses by $0.09 . Revenue of $14.85M (-91.9% Y/Y) misses by $16.54M . Cash Position. Cash, cash equivalents, and investments were $758.3M as of September 30, 2022, sufficient to fund current operatio...
Progressing enrollment in the INFRONT-3 Phase 3 pivotal study for latozinemab (AL001) and in the INVOKE-2 Phase 2 study for AL002 Initiated first-in-human Phase 1 trial of AL044, the company’s third novel, first-in-class clinical stage microglia immune checkpoint ther...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...